World of DTC Marketing

JANUARY 31, 2021

The venture capitalists funding them are looking for a big payday when a pharma company acquires them. I have been recruited by these companies who promise huge payouts when they are acquired if their drug shows promise in clinical trials. In pharma R&D returns have declined to 1.8 percent—a slight decrease of 0.1

In-Vivo 187

In-Vivo Generic Drugs Drugs Gene Therapy 187

Cloudbyz

MAY 19, 2021

Introduction Cell and gene therapy is an upcoming wave of therapeutic innovation in the healthcare and life sciences industry and is being pragmatically accepted worldwide. The gene therapy market reported its first market approvals back in 2017 and the evolution has been extensive ever since.

Gene Therapy 52

Gene Therapy Gene Manufacturing Production 52

XTalks

DECEMBER 20, 2023

“In 2024, pharma companies and emerging biotechs will improve candidate safety profiles and reduce off-target effects by exploiting predictive intelligence unlocked by AI,” she predicts. CRISPR Gene Editing Therapeutics CRISPR/Cas-9 technology makes lists like this almost every year, and for good reason.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

Delveinsight

SEPTEMBER 3, 2021

The post Charcot-Marie-Tooth Disease Market Size Expects Growth Owing to Increasing Prevalence, Influx of Pharma Companies and Novel Therapies appeared first on DelveInsight Business Research.

Pharma Companies 52

Pharma Companies Marketing Clinical Trials Clinical Trials 52

pharmaphorum

NOVEMBER 27, 2022

A group representing pharma companies selling precision therapies for cancer has called for a change to the way genomic testing is done in Scotland, to make sure patients get access to targeted drugs.

Genome 104

Genome Genomics Genetics Medicine 104

pharmaphorum

JANUARY 10, 2022

On the back of the approvals for Pfizer/BioNTech and Moderna, suddenly there is a large amount of interest from big pharma companies to get involved in the mRNA space. This not only allowed Pfizer to establish a COVID-19 vaccine but the company also recently announced that it had begun a study testing an mRNA flu vaccine.

RNA 111

RNA Vaccination Vaccine Pharma Companies 111

XTalks

DECEMBER 13, 2023

Now, let’s delve into the list of the top ten fastest growing biotech companies in 2023, ranked by their compound annual growth rate (CAGR). These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times.

Genetics 111

Genetics Vaccination Vaccine DNA 111

pharmaphorum

OCTOBER 12, 2022

Overall, the aim is to improve the efficiency of drug discovery by identifying genetic variants that contribute to human disease in omics data – a broad category that includes DNA profiles, gene transcripts, and protein expression.

Genome 64

Genome Genomics DNA Drugs 64

pharmaphorum

DECEMBER 23, 2020

The results also suggest further uses for the drug in early disease and more revenues to come from one of the company’s biggest success stories from the last decade. Pharma companies have also made headway in rare diseases as several pipeline projects came to fruition. Rare disease progress.

Marketing 96

Marketing Gene Gene Silencing Drugs 96

XTalks

OCTOBER 15, 2021

The cell line, called HeLa, laid the foundation for many groundbreaking discoveries, including vaccines for the human papilloma virus (HPV) and polio; drugs for HIV and cancers; gene mapping; IVF treatment; and more recently, for crucial COVID-19 research. Fittingly, it was also used to develop the vaccine against cervical cancer.

Vaccination 105

Vaccination Vaccine Gene Mapping Doctor 105

pharmaphorum

APRIL 26, 2022

Research into the area is being made possible through advancements in technology, such as being able to sequence genes at scale, allowing researchers to gain more detailed genetic data on the microbiome.

Containment 115

Containment Development Production Drugs 115

Delveinsight

AUGUST 4, 2021

Similarly, genetics, immune response, and environmental factors also influence the occurrence of Neurological Conditions. With the advancement in technology, today diagnostics testing such as neurological examination, brain scans, genetic screening, and other tests are available to examine the occurrence of Neurological Conditions.

Marketing 98

Marketing Genetics Development Clinical Development 98

XTalks

DECEMBER 29, 2022

For example, on the pharma and biotech side, there has been growing demand for new drugs and biologics, from new classes of dual-action diabetes and weight loss drugs like Ozempic and Mounjaro to life-saving gene therapies. 1. Cell and Gene Therapies. Here are four life sciences trends to look out for in 2023.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

Delveinsight

AUGUST 6, 2020

Hereditary ATTR amyloidosis , also known as Familial ATTR, is an autosomal dominant disease and a result of mutations in the TTR gene, thus it is passed down from one generation to the next one. The hATTR diagnosis is mainly dependent on symptoms and can be confirmed via performing tissue biopsies, genetic testing, and imaging studies.

Protein 52

Protein Gene Silencing Marketing Gene 52

The Pharma Data

OCTOBER 20, 2020

MD Anderson has historically collaborated with biotechs and pharma companies to conduct cancer therapy research. Targeted therapies, genetic sequencing, gene editing, immunotherapies. Ochsner Health and LSU Health Shreveport have offered themselves as additional trial sites to increase patient access to studies. .

Clinical Trials 52

Clinical Trials Clinical Trials Gene Editing Trials 52

Pharma Marketing Network

FEBRUARY 27, 2025

So, how can pharma companies use content marketing to engage HCPs and patients effectively ? Pharma brands can develop: Whitepapers on clinical trials showcasing drug effectiveness. Publish thought leadership articles on digital health, AI in pharma, or precision medicine. Lets dive in.

Branding 52

Branding Marketing Compliance Pharma Companies 52

XTalks

DECEMBER 20, 2023

Check out this article to learn about the biotech companies that went public this year. The companies include a diverse range engaged in innovative approaches in areas like oncology, genetic medicines, inflammatory diseases, dermatology and cardiorenal therapy.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

XTalks

DECEMBER 22, 2021

RNA therapeutics hold promise as powerful treatments for diseases, including those that are genetic-based. The gene-editing tool CRISPR edits DNA using specialized strands of guide RNA and endogenous cellular mechanisms of RNA interference. RNA Therapeutics.

Life Science 98

Life Science RNA Vaccination Vaccine 98

pharmaphorum

OCTOBER 26, 2022

And the company lives its commitment to patient centricity through all its operations, Chiesi explained. For example, at the SSIEM Annual Symposium earlier this month, the company shared data on a new candidate for the treatment of Fabry disease, a rare genetic blood disorder. Caring for a global community. About Chiesi Group.

Development 96

Development Trials Marketing Life Science 96

The Pharma Data

DECEMBER 17, 2020

Most recently, Cadavid served as senior vice president and Head of Clinical Development at Fulcrum Therapeutics where he led the development of multiple small molecules for the treatment of genetically defined rare diseases. Smith joined SpringWorks at the company’s inception in 2017 and was a founding member of the management team.

Development 52

Development Gene Therapy Engineer Life Science 52

pharmaphorum

DECEMBER 6, 2022

A few decades ago, gathering genetic data on the scale of the 100,000 Genomes Project would have been unthinkable – it was only in 2003 that the entire human genome was mapped. There are also hopes that clues could be found as to what risk factors are involved in the development of the most difficult to understand diseases. Hope for patients.

Genome Project 98

Genome Project Research Genome Genomics 98

pharmaphorum

SEPTEMBER 1, 2020

This knowledge of genetics and the underlying cause of many diseases, including cancer, has resulted in powerful new drugs. In cancer, the pharma industry has begun producing immunotherapies, which do not act directly against the disease but instead enlist the immune system to fight against malignant tissues.

Medicine 145

Medicine Insulin Drugs Pharmacy 145

Delveinsight

FEBRUARY 12, 2021

Furthermore, GlaxoSmithKline is developing GSK3377794 (NY-ESO-1 T-cells; GSK ‘794), a NY-ESO-1-directed genetically modified autologous T-cell immunotherapy and is an engineered T-cell therapy. Genetic counseling and other symptomatic treatment also help. Argininosuccinic aciduria is a rare disease that is genetically inherited.

Marketing 52

Marketing Clinical Trials Clinical Trials Development 52

Delveinsight

DECEMBER 2, 2020

Some of the most common factors include: Genes – Genes are considered to play a small role in Rheumatoid Arthritis. Smoking – Cigarette smoking, coupled with the genetic factor, can increase the risk of developing Rheumatoid Arthritis. What are the Risk Factors for Developing Rheumatoid Arthritis?

Marketing 60

Marketing Hormones Antibody Development 60

Roots Analysis

AUGUST 13, 2024

Messenger ribonucleic acid (mRNA) is a type of single-stranded ribonucleic acid (RNA), which helps in transferring genetic information in order to produce proteins. Additionally, the companies are evaluating various mRNA delivery technologies in order to ensure efficient and safe delivery of mRNA-based drugs.

Vaccination 40

Vaccination Vaccine Manufacturing Protein 40

The Pharma Data

DECEMBER 30, 2020

It is a strong potential player in the gene therapy space. Its lead candidate is AMT-061, an AAV5-based gene therapy being evaluated for severe and moderately severe hemophilia B in the Phase III HOPE-B study. billion, Regenxbio is also a gene therapy company. UniQure has a market cap of $2.1 With a market cap of $1.6

Vaccination 52

Vaccination Vaccine Gene Therapy Trials 52

Pharmaceutical Technology

MARCH 20, 2023

Pharma companies and world health stand to benefit from new technologies, but it’s a tough time to be an investor – and an even tougher one for firms seeking investment. Research – and money – going into even more advanced gene therapies is ramping up. Further rate hikes could be on the way this year. Source: GlobalData.

Gene Therapy 225

Gene Therapy Genome Genomics Gene 225

Pharmaceutical Technology

MAY 26, 2023

Enzymatic DNA production company Touchlight have augmented its DNA production capabilities with a newly announced expansion to its London facilities. Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines.

DNA 130

DNA Manufacturing Gene Gene Therapy 130

XTalks

JANUARY 6, 2025

Gene Editing CRISPR-Cas9 and related gene-editing technologies continue to advance, and today they are widely used to study and develop therapeutic approaches for a broad range of human diseases. Furthermore, CRISPR/Cas9 presents a promising avenue for overcoming genetic diseases in the near future. percent from 2022 to 2030.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111

XTalks

FEBRUARY 11, 2025

Gene therapy has shown promise in treating cancers that are particularly difficult to manage such as neuroblastoma and Wilms tumor using CAR-T cell therapy, CRISPR-Cas9 gene editing and RNA-based interventions to target genetic drivers of disease.

Gene Therapy 66

Gene Therapy Clinical Trials Clinical Trials Trials 66